Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms

Although the first line of therapy for epithelial ovarian cancer typically consists of taxane-platinum combination therapy, many patients develop a platinum-resistant tumor within a year. Several previous studies have looked at this cross-resistance between cisplatin and anti-microtubule drugs, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Ruchi P., Kuhn, Skyler, Yin, Da, Hotz, Jordan, Maher, Frances A., Robey, Robert W., Gottesman, Michael M., Horibata, Sachi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586247/
https://www.ncbi.nlm.nih.gov/pubmed/33129114
http://dx.doi.org/10.1016/j.tranon.2020.100917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586247/
https://www.ncbi.nlm.nih.gov/pubmed/33129114
http://dx.doi.org/10.1016/j.tranon.2020.100917

Ejemplares similares